A subset of digital health called “digital therapeutics” uses high-quality software to power evidence-based treatments in order to manage, treat or prevent medical conditions. To treat, prevent, or manage medical conditions like CHF, Type-2 Diabetes, Alzheimer’s disease, obesity, asthma, dementia, ADHD, anxiety, hypertension, depression, and & mobile health (mHealth), the industry offers appropriate therapeutic interventions for patients utilizing some highly-advanced software programs and devices. These strategies are based on cognitive behavioral therapy. To provide proper patient care and enhance health outcomes, the software application may be utilized alone or in combination with other tools, drugs, or treatments.
The Digital Therapeutics Market’s worth was $ 3.02 billion in 2021 & is expected to value at $ 31.79 billion by 2030, at almost 31.41% CAGR.
Digital Therapeutics inculcates a plethora of advantages, such as:
- Being a relatively new idea, it promises a lot of advantages for doctors, distributors, healthcare professionals, stakeholders, and of course, the patients.
- Patients now have access to tried-and-true medical innovations that are simple to use and improvise health outcomes. They also receive individualized care and treatment plans, which are significantly more successful due to tight adherence to the therapy schedule.
- Clinicians save information that can be used to further modify the patient management plan and track the efficacy of their treatment regimens.
Digital Therapeutics future, trends & its related statistics.
- There are two crucial areas associated with D.T.s that can entirely change the market outlook in the future:
DTx development with the help of curation platforms:-
They are crucial for scalability and speed to market. By implementing these platforms, DTx enterprises may take benefit of the built-in infrastructure as well as security features while concentrating on their core competencies (science).
Innovations
As emerging technologies mature, the success rate of DTx solutions will primarily depend on their capacity to tap into their potential. Promising technologies that demand a unique position on the DTx roadmap include smart advisors, cognitive computing, biochips, efficient computing, volumetric and holographic displays, haptic sensations, along with natural language queries.
- Digital treatments have increased the use of artificial intelligence (A.I.), virtual reality, and other technologies in the field of healthcare to address a wide range of issues. A.I. contributes significantly to digital therapies by raising patient adherence to software-based interventions. Digital therapies powered by A.I. offer appropriate diagnosis and individualized therapy in addition to foreseeing a range of obstacles and needs depending on patient behavior. For instance, the introduction of A.I. in digital therapies has effectively aided medical practitioners in understanding the daily routines and needs of the patients, allowing them to offer much better direction and assistance. Additionally, early signs of several major diseases, such as diabetes, dementia, Alzheimer’s disease, etc., can be quickly identified due to the use of A.I. in digital treatments.
- Future prospects for digital therapies are likely to present significant opportunities in developing nations, including China, the Middle East, and India. The governments of these nations are heavily funding research and development projects in order to significantly improve digital therapeutic technology.
Application Insights
The diabetes application section represented the biggest portion of over 28.5% of the worldwide income in 2021. Factors driving the section development incorporate the rising pervasiveness of diabetes and other persistent infections. Computerized therapeutics can help medical services suppliers to survey patients’ lives and work on the course of therapy in view of their singular remedial requirements
Segments incorporated within the report:-
Sales Channel
- B2B
- Payers
- Providers
- Pharmaceutical Companies
- Employers
- Others
- B2C
- Caregivers
- Patients
Product Type
- Device
- Software
Application
- Preventive Applications
- Treatment or Care-related Applications
- CNS Disorders
- Mental Health Disorders
- Others
- Diabetes
- Musculoskeletal Disorders
- Chronic Respiratory Disorders
- CVDs
- Medication Adherence
- Smoking Cessation
- Substance Use & Addiction Management
- Gastrointestinal Disorders
- Rehabilitation
- Patient Care
- Others
Players involved:
- Fitbit
- Happify
- Livongo Health
- Pear Therapeutics
- Omada Health
- Resmed
- Proteus Digital Health
- Welldoc
- Voluntis
- F-star Therapeutics
Recent Development
- On April 2022. Welldoc and Dexcom collaborated to launch BlueStar, a single platform with digital-health solutions for improving. The health of Type-2 Diabetes patients. Through this novel app, this cooperation combined. The two most difficult aspects of managing diabetes: glucose monitoring & the various effects of lifestyle decisions. Users will be able to manage various aspects of their health, and the method of data sharing with. Their respective care teams will also be improved.
- On March 2022. The CMS/Centres for Medicare & Medicaid Services created a new code to reflect prescription digital behavioral therapy. That had received FDA clearance in response to Pear Therapeutics’ application. The code inculcates digital prescription medicines like reSET-O, Pear’s reSET, and Somryst. That are FDA-approved for treating chronic insomnia, opioid user disorder, and various other disorders.
